OpGen, Inc. [NASDAQ: OPGN] revealed that it has entered into a strategic collaboration deal with the New York State Department of Health. The focus of this deal is to develop a modern solution to identify, trace, and control antimicrobial-resistant infections at healthcare institutions statewide.
This deal is being continued ahead of the second-year development phase by another six months through September 30, 2021. OpGen has successfully attained all the discoveries of the first and second-year phases for the expansion of infectious disease digital health.
Now, OPGN is endeavoring to collaborate with Wadsworth Center of DOH and the participating healthcare systems. The main aim of the firm is to increase the reach of the platform, boost the volume of testing, and optimize data collection.
The ongoing pandemic has caused a reduction in testing throughout 2020. So, the expansion and extension phase enables all stakeholders to create more data as testing volumes have been growing considerably from the fall of 2020 month by month until the close of March 2021 to date.
Furthermore, OpGen, DOH along all the stakeholders will continue to work collaboratively to illustrate that sustainable, flexible infectious diseases reporting, tracing, and monitoring tools for antimicrobial protection can be applied across New York State.
The firm disclosed that it is a great breakthrough for the firm as the department has decided to continue collaborating with it. Shares of the firm soared 0.44% at $2.2900 during the pre-market trading session of Monday.